

DAFTAR PUSTAKA

- Abubakari, S., Dizman, Y.A. and Karaman, F. (2025) 'Integrated Meta-Analysis Identifies Keratin Family Genes and Associated Genes as Key Biomarkers and Therapeutic Targets in Metastatic Cutaneous Melanoma', *Diagnostics*, 15(14), p. 1770. Available at: <https://doi.org/10.3390/diagnostics15141770>.
- Amaral, T. *et al.* (2017) 'The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition', *European Journal of Cancer*, 73, pp. 85–92. Available at: <https://doi.org/10.1016/j.ejca.2016.12.010>.
- Arnold, M. *et al.* (2022) 'Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040', *JAMA Dermatology*, 158(5), p. 495. Available at: <https://doi.org/10.1001/jamadermatol.2022.0160>.
- Avery-Kiejda, K.A. *et al.* (2011) 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', *BMC Cancer*, 11(1), p. 203. Available at: <https://doi.org/10.1186/1471-2407-11-203>.
- Baranwal, S. and Alahari, S.K. (2009) 'Molecular mechanisms controlling E-cadherin expression in breast cancer', *Biochemical and Biophysical Research Communications*, 384(1), pp. 6–11. Available at: <https://doi.org/10.1016/j.bbrc.2009.04.051>.
- Caramel, J. *et al.* (2013) 'A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma', *Cancer Cell*, 24(4), pp. 466–480. Available at: <https://doi.org/10.1016/j.ccr.2013.08.018>.
- Chen, Y. *et al.* (2022) 'Exosomal miR-22-3p from Mesenchymal Stem Cells Inhibits the Epithelial-Mesenchymal Transition (EMT) of Melanoma Cells by Regulating LGALS1', *Frontiers in Bioscience-Landmark*, 27(9). Available at: <https://doi.org/10.31083/j.fbl2709275>.
- Corrales, E. *et al.* (2022) 'PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma', *Cell Communication and Signaling*, 20(1), p. 187. Available at: <https://doi.org/10.1186/s12964-022-00989-y>.
- Cui, S. *et al.* (2025) 'miRTarBase 2025: updates to the collection of experimentally validated microRNA–target interactions', *Nucleic Acids Research*, 53(D1), pp. D147–D156. Available at: <https://doi.org/10.1093/nar/gkae1072>.
- Debnath, P. *et al.* (2022) 'Epithelial–mesenchymal transition and its transcription factors', *Bioscience Reports*, 42(1). Available at: <https://doi.org/10.1042/BSR20211754>.
- Deng, Y. *et al.* (2011) 'MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines', *International Journal of Biological Sciences*, 7(1), pp. 133–137. Available at: <https://doi.org/10.7150/ijbs.7.133>.
- Ding, L. and Liang Ruihua (2022) 'MiR-218-5p regulates proliferation and apoptosis of NSCLC cells by inhibiting NRAS expressions', *Aviation Medicine of Air Force*, 39(2).
- Eisfeld, A.-K. *et al.* (2014) 'NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation', *Proceedings of the National Academy of*

- Sciences*, 111(11), pp. 4179–4184. Available at:
<https://doi.org/10.1073/pnas.1401727111>.
- Fan, T. *et al.* (2022) ‘The overall process of metastasis: From initiation to a new tumor’, *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1877(4), p. 188750. Available at: <https://doi.org/10.1016/j.bbcan.2022.188750>.
- Gajos-Michniewicz, A. and Czyz, M. (2019) ‘Role of miRNAs in Melanoma Metastasis’, *Cancers*, 11(3), p. 326. Available at: <https://doi.org/10.3390/cancers11030326>.
- Garibaldi, F. *et al.* (2016) ‘Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex’, *Oncogene*, 35(29), pp. 3760–3770. Available at: <https://doi.org/10.1038/onc.2016.51>.
- Georgakilas, A.G., Martin, O.A. and Bonner, W.M. (2017) ‘p21: A Two-Faced Genome Guardian’, *Trends in Molecular Medicine*, 23(4), pp. 310–319. Available at: <https://doi.org/10.1016/j.molmed.2017.02.001>.
- Gershenwald, J.E. *et al.* (2017) ‘Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual’, *CA: A Cancer Journal for Clinicians*, 67(6), pp. 472–492. Available at: <https://doi.org/10.3322/caac.21409>.
- Guo, Z. *et al.* (2023) ‘HOXB9 a miR-122–5p regulated gene, suppressed the anticancer effects of brusatol by upregulating SCD1 expression in melanoma’, *Biomedicine & Pharmacotherapy*, 162, p. 114650. Available at: <https://doi.org/10.1016/j.biopha.2023.114650>.
- Gureghian, V. *et al.* (2023) ‘A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma’, *Cancer Gene Therapy*, 30(10), pp. 1330–1345. Available at: <https://doi.org/10.1038/s41417-023-00640-z>.
- Hao, L. *et al.* (2012) ‘Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail’, *British Journal of Dermatology*, 166(6), pp. 1184–1197. Available at: <https://doi.org/10.1111/j.1365-2133.2012.10824.x>.
- Hung, C. *et al.* (2025) ‘Recent Developments in Targeting the Cell Cycle in Melanoma’, *Cancers*, 17(8), p. 1291. Available at: <https://doi.org/10.3390/cancers17081291>.
- Joshi, S.S. and Hornyak, T.J. (2020) ‘Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle’, *Journal of Investigative Dermatology*, 140(4), pp. 743–745. Available at: <https://doi.org/10.1016/j.jid.2019.11.025>.
- Kim, D. and Yu, Y. (2024) ‘RNA expression-based risk stratification of stage III cutaneous melanoma.’, *Journal of Clinical Oncology*, 42(16_suppl), pp. e21551–e21551. Available at: https://doi.org/10.1200/JCO.2024.42.16_suppl.e21551.
- Korpal, M. *et al.* (2008) ‘The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2’, *Journal of Biological Chemistry*, 283(22), pp. 14910–14914. Available at: <https://doi.org/10.1074/jbc.C800074200>.
- Li, D. *et al.* (2023) ‘Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms’, *Cell Proliferation*, 56(6). Available at: <https://doi.org/10.1111/cpr.13423>.

- Lin, S. and Gregory, R.I. (2015) 'MicroRNA biogenesis pathways in cancer', *Nature Reviews Cancer*, 15(6), pp. 321–333. Available at: <https://doi.org/10.1038/nrc3932>.
- Liu, S., Tetzlaff, M.T., *et al.* (2012) 'Loss of microRNA-205 expression is associated with melanoma progression', *Laboratory Investigation*, 92(7), pp. 1084–1096. Available at: <https://doi.org/10.1038/labinvest.2012.62>.
- Liu, S., Kumar, S.M., *et al.* (2012) 'MicroRNA-9 up-regulates E-cadherin through inhibition of NF- κ B1–Snail1 pathway in melanoma', *The Journal of Pathology*, 226(1), pp. 61–72. Available at: <https://doi.org/10.1002/path.2964>.
- Long, J. and Pi, X. (2018) 'lncRNA-MEG3 Suppresses the Proliferation and Invasion of Melanoma by Regulating CYLD Expression Mediated by Sponging miR-499-5p', *BioMed Research International*, 2018, pp. 1–15. Available at: <https://doi.org/10.1155/2018/2086564>.
- Madrigal, T. *et al.* (2021) 'Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer', *Frontiers in Cell and Developmental Biology*, 9. Available at: <https://doi.org/10.3389/fcell.2021.695723>.
- Margue, C. *et al.* (2015) 'Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?', *Oncotarget*, 6(14), pp. 12110–12127. Available at: <https://doi.org/10.18632/oncotarget.3661>.
- Mo, Y. *et al.* (2019) 'MicroRNA-329 upregulation impairs the HMGB2/ β -catenin pathway and regulates cell biological behaviors in melanoma', *Journal of Cellular Physiology*, 234(12), pp. 23518–23527. Available at: <https://doi.org/10.1002/jcp.28920>.
- Nabipoorashrafi, S.A. *et al.* (2020) '<sc>miR</sc> -143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitro', *IUBMB Life*, 72(9), pp. 2034–2044. Available at: <https://doi.org/10.1002/iub.2345>.
- Noori, J., Sharifi, M. and Haghjooy Javanmard, S. (2018) 'miR-30a Inhibits Melanoma Tumor Metastasis by Targeting the E-cadherin and Zinc Finger E-box Binding Homeobox 2.', *Advanced biomedical research*, 7, p. 143. Available at: https://doi.org/10.4103/abr.abr_146_18.
- Pedri, D. *et al.* (2022a) 'Epithelial-to-mesenchymal-like transition events in melanoma', *The FEBS Journal*, 289(5), pp. 1352–1368. Available at: <https://doi.org/10.1111/febs.16021>.
- Pedri, D. *et al.* (2022b) 'Epithelial-to-mesenchymal-like transition events in melanoma', *The FEBS Journal*, 289(5), pp. 1352–1368. Available at: <https://doi.org/10.1111/febs.16021>.
- Pei, G. *et al.* (2017) 'FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR γ /miR-125b/Stat3 signaling pathway in B16F10 melanoma cells', *Oncotarget*, 8(8), pp. 13898–13908. Available at: <https://doi.org/10.18632/oncotarget.14687>.
- Peres, J. *et al.* (2017) 'The tumour suppressor, miR-137, inhibits malignant melanoma migration by targeting the TBX3 transcription factor', *Cancer Letters*, 405, pp. 111–119. Available at: <https://doi.org/10.1016/j.canlet.2017.07.018>.
- Prodan, M. *et al.* (2024) 'Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient

- Stages', *Biomedicines*, 12(12), p. 2809. Available at: <https://doi.org/10.3390/biomedicines12122809>.
- Sahranavardfard, P. *et al.* (2021) 'An Integrative Analysis of The Micro-RNAs Contributing in Stemness, Metastasis and B-Raf Pathways in Malignant Melanoma and Melanoma Stem Cell.', *Cell journal*, 23(3), pp. 261–272. Available at: <https://doi.org/10.22074/cellj.2021.7311>.
- Scarola, M. *et al.* (2010) 'miR-335 Directly Targets Rb1 (pRb/p105) in a Proximal Connection to p53-Dependent Stress Response', *Cancer Research*, 70(17), pp. 6925–6933. Available at: <https://doi.org/10.1158/0008-5472.CAN-10-0141>.
- Schadendorf, D. *et al.* (2018) 'Melanoma', *The Lancet*, 392(10151), pp. 971–984. Available at: [https://doi.org/10.1016/S0140-6736\(18\)31559-9](https://doi.org/10.1016/S0140-6736(18)31559-9).
- Seyfried, T.N. and Huysentruyt, L.C. (2013) 'On the origin of cancer metastasis.', *Critical reviews in oncogenesis*, 18(1–2), pp. 43–73. Available at: <https://doi.org/10.1615/critrevoncog.v18.i1-2.40>.
- Shain, A.H. *et al.* (2015) 'The Genetic Evolution of Melanoma from Precursor Lesions', *New England Journal of Medicine*, 373(20), pp. 1926–1936. Available at: <https://doi.org/10.1056/NEJMoa1502583>.
- Shang, Y. *et al.* (2024) 'Transcriptomics analysis of <sc>LINC02202</sc> / <sc>XBP1</sc> axis in melanoma: Implications for drug targeting and <sc>PD</sc>-1 monoclonal antibody efficacy', *Journal of Cellular and Molecular Medicine*, 28(8). Available at: <https://doi.org/10.1111/jcmm.18247>.
- Shojaei, S. *et al.* (2023) 'Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial–mesenchymal transition and angiogenesis in triple-negative breast cancer cells', *European Journal of Medical Research*, 28(1), p. 516. Available at: <https://doi.org/10.1186/s40001-023-01463-2>.
- Sicairos, B., Alam, S. and Du, Y. (2023) 'A comprehensive analysis of different types of databases reveals that CDH1 mRNA and E-cadherin protein are not downregulated in most carcinoma tissues and carcinoma cell lines', *BMC Cancer*, 23(1), p. 441. Available at: <https://doi.org/10.1186/s12885-023-10916-0>.
- Terranova, C.J. *et al.* (2021) 'Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy', *Cell Reports*, 36(3), p. 109410. Available at: <https://doi.org/10.1016/j.celrep.2021.109410>.
- Tomczak, K., Czerwińska, P. and Wiznerowicz, M. (2015) 'Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge', *Współczesna Onkologia*, 1A, pp. 68–77. Available at: <https://doi.org/10.5114/wo.2014.47136>.
- Tsoi, J. *et al.* (2018) 'Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress', *Cancer Cell*, 33(5), pp. 890-904.e5. Available at: <https://doi.org/10.1016/j.ccell.2018.03.017>.
- Welch, D.R. and Hurst, D.R. (2019) 'Defining the Hallmarks of Metastasis.', *Cancer research*, 79(12), pp. 3011–3027. Available at: <https://doi.org/10.1158/0008-5472.CAN-19-0458>.
- Wenzina, J. *et al.* (2020) 'Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma', *Journal of Investigative Dermatology*, 140(4), pp. 878-890.e5. Available at: <https://doi.org/10.1016/j.jid.2019.08.451>.

- Xie, Q. *et al.* (2023) 'Neuropilin-2 Inhibits Drug Resistance and Progression of Melanoma Involving the MiR-331-3p Regulated Cascade', *Current Molecular Pharmacology*, 16(7). Available at: <https://doi.org/10.2174/1874467216666221220111756>.
- Yang, C. *et al.* (2019) 'MicroRNA-139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K/AKT signaling pathway by binding to IGF1R', *Cell Cycle*, 18(24), pp. 3513–3524. Available at: <https://doi.org/10.1080/15384101.2019.1690881>.
- Yang, J. *et al.* (2020) 'Guidelines and definitions for research on epithelial–mesenchymal transition', *Nature Reviews Molecular Cell Biology*, 21(6), pp. 341–352. Available at: <https://doi.org/10.1038/s41580-020-0237-9>.
- Yu, H. and Yang, W. (2016) 'MiR-211 is epigenetically regulated by DNMT1 mediated methylation and inhibits EMT of melanoma cells by targeting RAB22A', *Biochemical and Biophysical Research Communications*, 476(4), pp. 400–405. Available at: <https://doi.org/10.1016/j.bbrc.2016.05.133>.
- Yuan, K., Sun, Y. and Ji, Y. (2021) 'miR-509-3p Suppresses Migration, Invasion, and Epithelial- Mesenchymal Transition in Melanoma Cells by Targeting Collagen Triple Helix Repeat Containing 1.', *Balkan medical journal*, 38(3), pp. 177–182. Available at: <https://doi.org/10.5152/balkanmedj.2021.20049>.
- Zhang, P. *et al.* (2015) 'MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2', *Toxicology Letters*, 234(3), pp. 151–161. Available at: <https://doi.org/10.1016/j.toxlet.2015.02.018>.
- Zhou, J. *et al.* (2014) 'miR-199a-5p regulates the expression of metastasis-associated genes in B16F10 melanoma cells.', *International journal of clinical and experimental pathology*, 7(10), pp. 7182–90.

GLOBOCAN 2022. Available at: <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf> (Accessed: 25 February 2025).

Indonesia. Available at: <https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf> (Accessed: 25 February 2025).

The cancer genome atlas program (TCGA) (no date) *NCI.* Available at: <https://www.cancer.gov/ccg/research/genome-sequencing/tcga> (Accessed: 25 February 2025).